Legorreta
Principal executive officer pay for Legorreta, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Royalty Pharma plc (RPRX) FY2020–FY2025
Lagged peersTSR -25% vs peer group 95% over FY2020–FY2025
Paid for declineCAP $51,529,883→$82,508,112 while $100 invested went $113.15→$85.11 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $55.7M | $51.5M |
| FY2021 | $49.5M | $57.0M |
| FY2022 | $93.5M | $45.8M |
| FY2023 | — | $26.8M |
| FY2024 | — | $191.3M |
| FY2025 | $937,500 | $82.5M |
The company's "$100 invested" index ran $113.15 at FY2020 → $85.11 by FY2025 — an annualized return of -5.5%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -5.5%/yr at RPRX ( FY2020–FY2025). See the CEO track-record ranking for context.